Keyphrases
Renal Cell Carcinoma
100%
MTOR Inhibitor
100%
Vascular Disrupting Agents
100%
Tumor
57%
Xenograft
42%
Combination Treatment
42%
Renca
42%
ASA404
42%
Everolimus
42%
Therapeutic Efficacy
28%
Histopathological Examination
14%
Angiogenesis
14%
Human Umbilical Vein Endothelial Cells (HUVECs)
14%
Tumor Growth
14%
CD31
14%
Hypoxia
14%
Necrosis
14%
Malignancy
14%
In Vitro Study
14%
Histologic
14%
Vascular Reactivity
14%
Growth Estimates
14%
Novel Combinations
14%
Antiangiogenic Agents
14%
3D Spheroids
14%
5,6-dimethylxanthenone-4-acetic Acid
14%
Blood Volume
14%
Combination Therapy
14%
Combination Strategy
14%
Vadimezan
14%
Spheroid Formation Assay
14%
Measurement Evaluation
14%
Endothelial Sprouting
14%
Patient Tumor
14%
DMXAA
14%
Vascular Damage
14%
RAD001
14%
Tumor Section
14%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Mammalian Target of Rapamycin
100%
Vadimezan
85%
Neoplasm
57%
Everolimus
57%
Xenograft
42%
Combination Therapy
42%
Magnetic Resonance Imaging
28%
Vascular Tissue Neoplasm
28%
Vascular-Targeting Agent
28%
Mammalian Target of Rapamycin Inhibitor
28%
In Vitro
14%
Tumor Progression
14%
Necrosis
14%
Hypoxia
14%
Cancer
14%
Human Umbilical Vein Endothelial Cell
14%
Angiogenesis
14%
Tumor Spheroid
14%
Blood Vessel Reactivity
14%
Angiogenesis Inhibitor
14%
Blood Vessel Injury
14%
Endothelial Cell Sprouting
14%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Vadimezan
85%
Neoplasm
57%
Everolimus
57%
Combination Therapy
42%
Mammalian Target of Rapamycin Inhibitor
28%
Vascular Tumor
28%
Vascular Targeting Agent
28%
Necrosis
14%
Tumor Growth
14%
Hypoxia
14%
Angiogenesis Inhibitor
14%
Blood Vessel Injury
14%